At a glance

What is humanin?

Humanin is a naturally occurring 24-amino acid peptide encoded within the mitochondria, the energy-producing structures of cells. It belongs to a family of "mitochondrial-derived peptides" and has drawn research interest in aging and neuroprotection. It is sold through wellness and "research peptide" channels for longevity, and it is not an approved medicine.

How does it work?

Humanin is proposed to:

• Protect cells
• Support nerve-cell survival
• Reduce programmed cell death
• Improve insulin sensitivity¹ and metabolic signaling

Its levels are reported to decline with age in some studies and to rise in others, and are reported lower in some diseases. In laboratory and animal work it protected neurons and, in worms and mice, was associated with extended lifespan and healthspan. These are preclinical findings. This describes the proposed mechanism, separate from demonstrated benefit in people.

Is it FDA-approved?

No. Humanin is not approved by the FDA or any regulator as a therapy; it is studied as a research tool and sold through gray-market channels. It is not on FDA compounding lists and was not among the peptides reviewed at the 2026 FDA compounding advisory meetings.

What does the research show?

The evidence is preclinical and observational. The table below summarizes what each type of study, as indexed on PubMed, has found.

Frequently asked questions

Is humanin FDA-approved?

No. Humanin is not FDA-approved for any human indication. No NDA or BLA for humanin has been approved as of September 2026. It has no established compounding pathway and is not legally marketed for human use in the United States.

Is humanin legal in the United States?

Humanin is not an approved drug and is not a controlled substance⁴. However, it has no legal pathway for human therapeutic use. Products sold online as humanin are marketed as "research use only," which means they fall outside FDA pharmaceutical regulation. Purchasing them for personal use exists in a legal gray zone that does not confer safety assurances.

Can a doctor prescribe humanin?

No. Humanin is not FDA-approved and has no established 503A or 503B compounding classification, meaning it cannot be prescribed or compounded by a licensed pharmacy for patient use in the United States. No legal prescribing pathway exists as of September 2026.

What is the difference between humanin and MOTS-c?

Both are mitochondrial-derived peptides (MDPs) encoded within mitochondrial DNA, but they have distinct sequences, mechanisms, and research foci. Humanin is a 24-amino-acid peptide studied primarily for cytoprotection, neuroprotection, and the IGF-1/IGFBP-3 signaling axis⁵. MOTS-c is a 16-amino-acid peptide studied primarily for metabolic effects, particularly glucose regulation and exercise adaptation. They share the MDP classification and a relationship to aging biology but are pharmacologically distinct compounds with separate evidence bases. This comparison is for scientific context only; these compounds have fundamentally different research profiles and neither has an approved human therapeutic indication.

What does the human data on humanin actually show?

Human data on humanin is observational only, and the findings are mixed. Some studies report a decline with age⁵, while a cohort of 693 people aged 21 to 113 found higher plasma humanin in older age⁶, with the highest levels in centenarians. A later study found lower humanin in Alzheimer's disease⁷ but not in type 2 diabetes, and a genetic variant linked to lower circulating humanin⁸ was associated with faster cognitive aging. These correlations are hypothesis-generating; they do not establish causality or support therapeutic use.

What is the S14G-humanin (HNG) analog?

HNG is a synthetic analog of native humanin in which the amino acid at position 14 is changed from serine to glycine. Laboratory research reports that this substitution produces approximately 1,000-fold greater potency⁹ in neuroprotection assays compared to the native sequence. HNG and native humanin are distinct compounds with different potency profiles and potentially different safety considerations, though neither has human safety data.

Did FDA's April 2026 peptide list change affect humanin?

No. In April 2026, FDA removed a group of peptides from its Category 2 list¹⁰ after the nominators withdrew their nominations, which was not a finding that those substances are safe. Humanin is not on any FDA category list¹¹, so its status is unchanged: no FDA-approved formulation exists, and no compounding pathway has been established.

Are peptides legal in 2026?

The legality of specific peptides varies by compound. Some peptides (such as bremelanotide¹² and tesamorelin¹³) have FDA-approved indications. Others, including humanin, have no approved therapeutic use and no compounding classification. FDA's April 2026 changes to its Category 2 list do not create a legal pathway for compounds like humanin that are not on any FDA category list. Consulting a licensed healthcare provider is the appropriate step for any questions about specific compounds.

More for hormones & metabolism